NCT00498342 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Solomon R, Barrett B
Follow-up of patients with contrast-induced nephropathy. Kidney Int Suppl. 2006 Apr;(100):S46-50.
Solomon R, Briguori C, Bettmann M
Selection of contrast media. Kidney Int Suppl. 2006 Apr;(100):S39-45. Review. Erratum in: Kidney Int Suppl. 2006 Dec;70(12):2156. Biguori, C [corrected to Briguori, C].
Solomon R, Deray G; Consensus Panel for CIN
How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006 Apr;(100):S51-3.
Solomon R
Contrast media nephropathy--how to diagnose and how to prevent? Nephrol Dial Transplant. 2007 Jul;22(7):1812-5. Epub 2007 Apr 20. Review.
Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE; Investigators of the CARE Study
Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007 Jun 26;115(25):3189-96. Epub 2007 Jun 11.

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

Clinical trial NCT00498342 - References